FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Breast Cancer Drug OKd 2 Months Ahead of Goal Date

[ Price : $8.95]

Two months ahead of its user fee review goal, FDA approves Puma Biotechnologys Nerlynx (neratinib) in combination with capecitabin...

FDA Exploring CBD Regulatory Paths

[ Price : $8.95]

FDA commissioner Stephen Hahn says FDA is using the best available science to evaluate possible non-drug regulatory pathways for C...

Unapproved Drugs Initiative Hiking Healthcare Costs: Analysis

[ Price : $8.95]

Vizient says a consequence of FDA approval of four drugs under its Unapproved Drugs Initiative is an increase in health system spe...

Y-mAbs Plans Rolling BLA for Omburtamab

[ Price : $8.95]

Y-mAbs Therapeutics says it will complete in 10 weeks a rolling BLA for omburtamab for treating patients with central nervous syst...

Takeda sNDA for Alunbrig Expanded Use

[ Price : $8.95]

FDA grants Takeda Pharmaceutical Co. a priority review for its supplemental NDA that seeks to expand the use of Alunbrig (brigatin...

CGMP Violations at Essnd Global

[ Price : $8.95]

FDA warns Indias Essnd Global about CGMP violations in its work as a contract manufacturer of finished drugs.

Unetixs Vascular QS Violations

[ Price : $8.95]

FDA warns Unetixs Vascular about Quality System violations in its manufacturing of vascular diagnostic ultrasound systems.

CGMP Violations Seen in KVK-Tech Inspection

[ Price : $8.95]

FDA warns KVK-Tech about CGMP violations in its production of finished drugs.

FDA Takes Power Morcellator Safety Steps

[ Price : $8.95]

FDA announces three steps intended to make use of laparoscopic power morcellators in gynecologic surgeries.

Genentech BLA for Perjeta, Herceptin & Chemo Combo

[ Price : $8.95]

FDA accepts for review a Genentech BLA for a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyalu...